2 research outputs found
Once-daily fluticasone furoate/vilanterol <i>versus</i> twice-daily fluticasone propionate/salmeterol in patients with asthma well controlled on ICS/LABA
<p><i>Objective</i>: We aimed to demonstrate non-inferiority of once-daily fluticasone furoate/vilanterol 100/25 ¾g (FF/VI) to twice-daily fluticasone propionate/salmeterol 250/50 ¾g (FP/SAL) in adults/adolescents with asthma well controlled on inhaled corticosteroid/long-acting β<sub>2</sub> agonist (ICS/LABA). <i>Methods</i>: This was a randomized, double-blind, double-dummy, parallel-group, 24-week study (NCT02301975/GSK study 201378). Patients whose asthma met study-defined criteria for control were randomized 1:1:1 to receive FF/VI, FP/SAL or twice-daily FP 250 ¾g for 24 weeks. Primary endpoint was change from baseline in evening trough forced expiratory volume in 1 second (FEV<sub>1</sub>). Secondary endpoints included rescue-/symptom-free 24-hour periods. Safety was also assessed. <i>Results</i>: The intent-to-treat (ITT) population included 1504 randomized and treated patients (504 FF/VI; 501 FP/SAL; 499 FP); mean age 43.5 years, 64% female. FF/VI demonstrated non-inferiority (using a margin of â100 mL) to FP/SAL for evening trough FEV<sub>1</sub> at Week 24 (ITT: 19 mL [95% confidence interval (CI) â11 to 49]; per protocol population [<i>N</i> = 1336]: 6 mL [95% CI â27 to 40]). Improvement in evening trough FEV<sub>1</sub> at Week 24 for both FF/VI (123 mL; <i>p</i> < 0.001) and FP/SAL (104 mL; <i>p</i> < 0.001) was greater than FP. FF/VI increased rescue-/symptom-free 24-hour periods by 1.2%/1.2% compared with FP/SAL. All treatments were well tolerated. On-treatment adverse event (AE) rates were 43% to 45% across arms; there were no drug-related serious AEs. <i>Conclusions</i>: FF/VI was non-inferior to FP/SAL for evening trough FEV<sub>1</sub> at 24 weeks. These data suggest that patients well controlled on FP/SAL could step across to FF/VI without loss of control.</p
An Integrated Analysis of Fluticasone Furoate/Vilanterol (FF/VI) Versus FF Safety Data Across Phase II and III Asthma Studies
<p><b>Article full text</b></p>
<p><br></p>
<p>The full text of this article can
be found here<b>. </b><a href="https://link.springer.com/article/10.1007/s41030-016-0015-1?view=classic">https://link.springer.com/article/10.1007/s41030-016-0015-1?view=classic</a></p><p></p>
<p><br></p>
<p><b>Provide enhanced content for this
article</b></p>
<p><br></p>
<p>If you are an author of this
publication and would like to provide additional enhanced content for your
article then please contact <a href="http://www.medengine.com/Redeem/âÂÂmailto:[email protected]âÂÂ"><b>[email protected]</b></a>.</p>
<p><br></p>
<p>The journal offers a range of
additional features designed to increase visibility and readership. All
features will be thoroughly peer reviewed to ensure the content is of the
highest scientific standard and all features are marked as âpeer reviewedâ to
ensure readers are aware that the content has been reviewed to the same level
as the articles they are being presented alongside. Moreover, all sponsorship
and disclosure information is included to provide complete transparency and
adherence to good publication practices. This ensures that however the content
is reached the reader has a full understanding of its origin. No fees are
charged for hosting additional open access content.</p>
<p><br></p>
<p>Other enhanced features include,
but are not limited to:</p>
<p><br></p>
<p>⢠Slide decks</p>
<p>⢠Videos and animations</p>
<p>⢠Audio abstracts</p>
<p>⢠Audio slides</p